To include your compound in the COVID-19 Resource Center, submit it here.

Nimbus Therapeutics, Gilead deal

Gilead will acquire the Nimbus Apollo Inc. subsidiary of Nimbus Therapeutics for $400

Read the full 130 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE